Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06174857 | RECRUITING | Advanced Non-Small Cell Lung Cancer

Efficacy of Osimertinib in Patients With Lung Cancer
Sponsor:

Hunan Province Tumor Hospital

Information provided by (Responsible Party):

Adult Zhang

Brief Summary:

This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.

Condition or disease

Advanced Non-Small Cell Lung Cancer

Study Type : OBSERVATIONAL
Estimated Enrollment : 100 participants
Official Title : Efficacy of Osimertinib in Patients With Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
Actual Study Start Date : 2021-01-01
Estimated Primary Completion Date : 2025-06-15
Estimated Study Completion Date : 2025-09-15

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Patients must be ≥18 years.
  • * Provision of fully informed consent prior to any study specific procedures.
  • * Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology.
  • * According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.
Exclusion Criteria
  • * None
Efficacy of Osimertinib in Patients With Lung Cancer

Location Details

NCT06174857

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

China, Hunan

Hunan Cancer hospital

Changsha, Hunan, China,